Research Focus

Oncology & Hematology

Area of Research

Translational immuno-oncological research on prostate and bladder cancer

2018           SAKK-RTF: Extended pelvic lymph node dissection vs. no pelvic lymph node dissection at radical prostatectomy for intermediate- and high-risk prostate cancer

2018           KLS: Extended pelvic lymph node dissection vs. no pelvic lymph node dissection at radical prostatectomy for intermediate- and high-risk prostate cancer

2019           KLBB: Extended pelvic lymph node dissection vs. no pelvic lymph node dissection at radical prostatectomy for intermediate- and high-risk prostate cancer 

The trial above was aborted in 2021 due to financial crisis of SAKK. New trial in development.

2022           KLBB (co-applicant): ProBio: An outcome-adaptive and randomized multiarm biomarker driven study in patients with metastatic prostate cancer 

2022           KFS (co-applicant): An organoid-based co-clinical pilot trial in metastatic prostate cancer" 

National Collaborations

• SAKK network including all major urological departments in Switzerland
• Hans Hirsch, University of Basel
• Lukas Bubendorf, University of Basel

International Collaborations

• Peter Black, Department of Urologic Sciences, University of British Columbia, Vancouver
• Alexander Wyatt, Genome Science and Technology, The University of British Columbia, Vancouver Prostate Centre, Vancouver

• Organization of Clinical Research Urology
• Ex vivo models for prostate and bladder cancer patients
• Observational study for patients undergoing BCG immunotherapy (including tissue, blood and urine bio-banking)
• Evaluation of liquid biopsy (NGS panels) in patients with advanced genitourinary cancers